Nuvalent Presents Preclinical Data Demonstrating That ROS1 Inhibitor NUV-520 and ALK Inhibitor NUV-655 are Selective, Brain-Penetrant, and Active Against Drug-Resistance Mutations

Share this article
Share this article
CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced preclinical data supporting advancement of its parallel lead programs in non-small cell lung cancer (NSCLC), including NUV-520 – a potential best-in-class ROS1-selective inhibitor – and NUV-655 – an ALK-selective inhibitor. Data are being presented at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting from April 10-15 in two separate poster presentations. Posters will be archived on the Nuvalent website at www.nuvalent.com.
In addition, Nuvalent announces the appointment of leading medical oncologist Alexander Drilon, M.D., to its Scientific Advisory Board (SAB). Dr. Drilon currently serves as Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSK) and brings deep expertise in early-phase clinical trials for cancer. At MSK, his research focuses on the development of novel therapeutics for cancer patients who have developed drug-resistance mutations.

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Jamesr Porter ,James Porter ,Joshuac Horan ,Nancye Kohl ,Henrye Pelish ,Matthewd Shair ,Alexander Drilon ,Anupong Tangpeerachaikul ,Prnewswire Nuvalent Inc ,American Association For Cancer Research ,Linkedin ,Nuvalent Inc ,Twitter ,Cancer Research ,Virtual Annual Meeting ,Scientific Advisory Board ,Early Drug Development Service ,Memorial Sloan Kettering Cancer Center ,Chief Executive Officer ,ஒன்றுபட்டது மாநிலங்களில் ,கேம்பிரிட்ஜ் ,கேம்பிரிட்ஜ்ஷைர் ,ஒன்றுபட்டது கிஂக்டம் ,அமெரிக்கன் ,ஜேம்ஸ் போர்டர் ,அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி ,சென்டர் ,ட்விட்டர் ,புற்றுநோய் ஆராய்ச்சி ,மெய்நிகர் ஆண்டு சந்தித்தல் ,ஆரம்ப மருந்து வளர்ச்சி சேவை ,நினைவகம் ஸ்லோன் கெட்டரிங் புற்றுநோய் மையம் ,தலைமை நிர்வாகி அதிகாரி ,